{"id":"pemetrexed-oral-folinic-acid-rescue","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"10-20","effect":"Mucositis"},{"rate":"20-30","effect":"Nausea and vomiting"},{"rate":"20-30","effect":"Fatigue"},{"rate":"5-10","effect":"Renal toxicity"},{"rate":"10-15","effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL2360464","moleculeType":"Small molecule","molecularWeight":"471.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pemetrexed is a multitargeted antifolate that disrupts thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, blocking DNA and RNA synthesis in rapidly dividing cells. Oral folinic acid (leucovorin) rescue is administered to replenish folate pools in normal tissues, reducing toxicity to bone marrow and gastrointestinal epithelium while maintaining pemetrexed's anticancer activity against tumor cells with different folate metabolism.","oneSentence":"Pemetrexed inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, and oral folinic acid rescue protects normal cells from toxicity while allowing cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:40:53.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malignant pleural mesothelioma"},{"name":"Non-small cell lung cancer"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT03656549","phase":"PHASE4","title":"Dose Individualization of Pemetrexed - IMPROVE-I","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2019-02-01","conditions":"Non Small Cell Lung Cancer, Mesothelioma","enrollment":6},{"nctId":"NCT06010277","phase":"PHASE4","title":"Folinic Acid for Prevention of Pemetrexed-induced Toxicity","status":"UNKNOWN","sponsor":"Amphia Hospital","startDate":"2023-02-06","conditions":"NSCLC, Mesothelioma, Thymoma","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Pemetrexed + oral folinic acid rescue","genericName":"Pemetrexed + oral folinic acid rescue","companyName":"Radboud University Medical Center","companyId":"radboud-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pemetrexed inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, and oral folinic acid rescue protects normal cells from toxicity while allowing cancer cell death. Used for Malignant pleural mesothelioma, Non-small cell lung cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}